Neurochem's strategic plan focuses on the research, development and commercialization of products to provide innovation health solutions to patients suffering from serious diseases.
With promising drug candidates currently in clinical trials and with expanding drug development programs, Neurochem is a company coming of age.
The Company was founded in 1993 by the technology transfer office of Queen's University, Parteq Research and Development Innovations, in Kingston, Ontario, Canada, to develop and commercialize small organic molecules. These molecules, discovered by lead researchers at the university, form the basis of Neurochem's unique technology. Today, Neurochem is proud to count on the dedication of a team of close to 200 researchers, management and staff.
To advance the development of its breakthrough technologies through clinical trial and commercialization phases, Neurochem has entered and continues to negotiate a variety of international R&D agreements, partnerships, collaborations and contracts with renowned scientists, researchers, academic institutions, pharmaceutical companies and contract research organizations, while maintaining the full ownership of its therapeutic rights.
Our site is best viewed with IE4+ at a resolution of 1024×768.
